IgA nephropathy is more common in young people and it is the most common type of primary glomerulonephritis.
IgA nephropathy is the most typical manifestation of hematuria, but it is not its development as a determinant of renal failure.
Urine protein, blood pressure, renal function in these three areas, is to determine whether patients with renal failure, and even uremic determinants.
1 Reduce proteinuria: For patients with urinary protein greater than 1g, regardless of blood pressure is increased, the general will be the preferred choice of drugs such as sartan and Puli, they not only have the effect of anti-hypertension, but also has the role of reducing urinary protein. For those who still can not make urinary protein less than 1g, hormone therapy can be combined, but pay attention to the amount.
2 Control of blood pressure: IgA nephropathy generally can cause high blood pressure, the process of treatment should actively control blood pressure, in order to prevent the concurrent heart and brain disease. At the same time, the control of blood pressure can also reduce kidney pressure, so as to avoid the adverse effects of hypertension on renal arterioles.
3 The protection of renal function: IgA nephropathy patients, timely replenishment of water to prevent infection, avoid the use of suspicious drugs to prevent the sharp deterioration of renal function. In patients with malignant hypertension, we must actively control blood pressure.
If urinary protein control in less than 0.5g, blood pressure control in the 130 / 80mmHg below the basic stability of renal function in patients with renal failure risk can be controlled to very low.
The treatment of IgA nephropathy is a long-term process, and many patients with renal failure are not out of control, but have not received normative long-term management at all.